Merck (MRK) Cash from Operations (2009 - 2026)
Merck (MRK) posted quarterly Cash from Operations of 3918000000.0 for Q1 2026, up 56.72% year-over-year from 2500000000.0 in Q1 2025, and up 37.14% quarter-over-quarter from 2857000000.0 in Q4 2025.
Merck (MRK) Cash from Operations (2009 - 2026) Analysis & Trends
Merck (MRK) has reported Cash from Operations for 18 consecutive years, with 3918000000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash from Operations rose 56.72% year-over-year to 3918000000.0; the TTM figure through Mar 2026 stood at 17890000000.0 (down 14.31% YoY), while the FY2025 annual figure was 16472000000.0, down 23.27% from the prior year.
- Cash from Operations advanced to 3918000000.0 in Q1 2026 per MRK's latest filing, from 2857000000.0 in the prior quarter.
- Across five years, Cash from Operations topped out at 9291000000.0 in Q3 2024 and bottomed at 246000000.0 in Q4 2023.
- Historically, Cash from Operations has averaged 4350529411.76 across 5 years, with a median of 3918000000.0 in 2026.
- Annual changes were most pronounced in 2023 — Cash from Operations slumped 94.45% — and 2024, when it surged 1302.44%.
- Merck's Cash from Operations stood at 4430000000.0 in 2022, then plunged by 94.45% to 246000000.0 in 2023, then soared by 1302.44% to 3450000000.0 in 2024, then decreased by 17.19% to 2857000000.0 in 2025, then jumped by 37.14% to 3918000000.0 in 2026.
- Business Quant data shows MRK's Cash from Operations at 3918000000.0 in Q1 2026, 2857000000.0 in Q4 2025, and 7822000000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 8.62 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 3.44 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 5.37 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 5.88 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | - |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 4.00 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 3.57 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 835.00 Mn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | - |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn | 2.55 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 5.37 Bn |
| Jun 30, 2026 | 5.37 Bn |
| Mar 31, 2026 | 3.92 Bn |
| Mar 31, 2026 | 3.92 Bn |
| Dec 31, 2025 | 2.86 Bn |
| Dec 31, 2025 | 2.86 Bn |
| Sep 30, 2025 | 7.82 Bn |
| Sep 30, 2025 | 7.82 Bn |
| Jun 30, 2025 | 3.29 Bn |
| Jun 30, 2025 | 3.29 Bn |
| Mar 31, 2025 | 2.50 Bn |
| Mar 31, 2025 | 2.50 Bn |
| Dec 31, 2024 | 3.45 Bn |
| Dec 31, 2024 | 3.45 Bn |
| Sep 30, 2024 | 9.29 Bn |
| Sep 30, 2024 | 9.29 Bn |
| Jun 30, 2024 | 5.64 Bn |
| Jun 30, 2024 | 5.64 Bn |
| Mar 31, 2024 | 3.09 Bn |
| Mar 31, 2024 | 3.09 Bn |